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As a key mediator of type I interferon (IFN) (IFN-/) responses, IFN regulatory factor 7 (IRF7) is essential
to host immune defenses. Activation of IRF7 generally requires virus-induced C-terminal phosphorylation,
which leads to its nuclear accumulation and activation of target genes. Here we use the Epstein-Barr virus
(EBV) oncoprotein LMP1, which activates IRF7, to identify factors involved in IRF7 activation. We demon-
strate for the first time that RIP activates IRF7 and that RIP and IRF7 interact under physiological conditions
in EBV-positive Burkitt’s lymphoma cells. We provide evidence that both RIP and IRF7 are ubiquitinated in
these cells and that IRF7 preferentially interacts with ubiquitinated RIP. RIP is required for full activation of
IRF7 by LMP1, with LMP1 stimulating the ubiquitination of RIP and its interaction with IRF7. Moreover,
LMP1 stimulates RIP-dependent K63-linked ubiquitination of IRF7, which regulates protein function rather
than proteasomal degradation of proteins. We suggest that RIP may serve as a general activator of IRF7,
responding to and transmitting the signals from various stimuli, and that ubiquitination may be a general
mechanism for enhancing the activity of IRF7.
Type I interferons (IFN), IFN-/, are critically important
in the defense against viral and bacterial infections and regu-
late both innate and adaptive immune responses as well as
affecting cell growth, differentiation, and survival (3, 29). Key
regulators of IFN-/ expression are IFN regulatory factor 7
(IRF7) and IRF3. IRF3 is constitutively expressed in most cell
types and is responsible for the induction of the early phase of
IFN-/ production after infection. IRF7 is expressed consti-
tutively at low levels in lymphoid cells and can be induced to
high levels in other cell types by IFN-/, lipopolysaccharide,
tumor necrosis factor alpha (TNF-), tetradecanoyl phorbol
acetate, virus infection, and the Epstein-Barr virus (EBV) on-
coprotein LMP1 (1, 23, 24, 44). The induced IRF7 primes the
cells for a second, more diverse wave of IFN-/ production
(26). IRF7 controls all type I IFN-dependent immune re-
sponses (11), which emphasizes its centrality in host immune
defenses and highlights the need to understand the mecha-
nisms regulating its activity.
Viral infection, Toll-like receptor (TLR) signaling, DNA-
damaging agents, and EBV LMP1 activate IRF7, marked by its
phosphorylation and accumulation in the nucleus (1, 8, 10, 16,
18, 32, 45). The IB kinase (IKK)-related kinases IKKε and
TBK1 phosphorylate C-terminal serine residues in IRF7 in
response to viral infection (34). In addition, IRAK1 phosphor-
ylates IRF7 in vitro and contributes to its activation by
TLR7/9 (37).
EBV, a gammaherpesvirus, is a human tumor virus. In ad-
dition to its lytic cycle in epithelial cells, a hallmark of EBV
infection is latent infection of B lymphocytes. EBV latent in-
fection is generally asymptomatic in immunocompetent indi-
viduals, but in immunocompromised persons it can produce
EBV-driven immunoblastic sarcomas as well as an increased
incidence of Burkitt’s lymphoma (30). The EBV latent mem-
brane protein LMP1 is the principal EBV oncoprotein and acts
as a constitutively active, ligand-independent, receptor-like
molecule. Signaling from LMP1 mimics many aspects of CD40
signaling (reviewed in reference 21), and recent studies indi-
cate that LMP1 signaling incorporates components of TLR
pathways as well (25, 33). LMP1 contains two domains in its
C terminus, C-terminal activation region 1 (CTAR1) and
CTAR2, that are predominantly responsible for its signaling
capacity. CTAR1 contains a PXQXT domain that binds mem-
bers of the TRAF family (TRAF-1, -2, -3, and -5). CTAR2
contains a YYD motif necessary for association with TRADD
and RIP (14). TRAF6 also participates in LMP1 signaling
most likely through indirect interactions with LMP1 (25,
33, 39).
RIP is a death domain-containing adaptor protein that as-
sociates with TNF receptors (TNFR) and is essential for TNF-
induced activation of NF-B (12, 17, 36). RIP also participates
in TLR signaling (27, 38) and has been implicated in activation
of IRF3 in response to double-stranded RNA (dsRNA) but
not formally linked to IRF7 (2). In addition, RIP associates
with LMP1 (14), although its role in LMP1 signaling remains
obscure. RIP possesses serine/threonine kinase activity and
undergoes autophosphorylation (12), although RIP’s kinase
activity is dispensable for many of its functions (13, 19, 36).
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RIP is modified by at least two forms of ubiquitination, K48-
linked and K63-linked polyubiquitination (41). K48-linked
ubiquitination typically leads to proteasomal degradation of
proteins, whereas K63-linked ubiquitination is implicated in
proteasome-independent functions that activate and/or regu-
late protein function (35). Ubiquitination of RIP is essential
for its signaling functions (19), and K63-linked ubiquitin (Ub)
chains have been proposed to provide a scaffold for the assem-
bly of signaling complexes (15).
We have shown previously that LMP1 promotes the phos-
phorylation and nuclear accumulation of IRF7 (45). IRF7 is
necessary for LMP1-induced up-regulation of Tap-2 expres-
sion (45) and has been implicated in LMP1-mediated priming
of EBV latently infected cells for production of type I IFN
(42). In this study, we examine LMP1 signaling events that lead
to the activation of IRF7. We demonstrate that RIP is involved
in activation of IRF7 by LMP1 and show that LMP1 promotes
the ubiquitination of RIP as well as interaction of ubiquiti-
nated RIP and IRF7. Moreover, LMP1 promotes RIP-depen-
dent ubiquitination of IRF7 conjugated at least in part through
Ub K63, suggesting that modification by Ub may modulate
IRF7 activity.
MATERIALS AND METHODS
Cell lines. HEK293 cells were maintained in Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum (FBS). RIP/ TNFR/ and RIP/
TNFR/ immortalized fibroblasts were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% FBS and 2 mM glutamine. All other
cell lines were maintained in RPMI with 10% FBS. SVT35 Jurkat T lymphoma
cells (parental) and RIP-deficient 35.3.13 Jurkat cells have been described pre-
viously and were a gift from Brian Seed (Massachusetts General Hospital, Bos-
ton) (36). Raji is a Burkitt’s lymphoma B-cell line. DG75-TA and DG75-LMP1
cell lines have been described elsewhere (9).
Plasmids and reagents. IRF7 in pcDNA3 and IRF7 in pcLMP1 have been
described previously (46, 47). Flag-IRF7 in pCMV2 and the IFN- promoter
construct were gifts of John Hiscott (McGill University, Canada) and have been
described previously (22). Wild-type RIP and kinase-dead RIP (kd-RIP) (K45A)
were provided by William Cance (University of Florida, Gainesville). Hemag-
glutinin-tagged Ub (HA-Ub) and HA-K63-only Ub (see below) in pcDNA3 were
generously provided by David Boone and Averil Ma (University of California,
San Francisco). Dominant negative TRAF6 (TRAF6DN) was provided by Arnd
Kieser (GSF National Research Center for Environment and Health, Germany).
The IFN-stimulated response element (ISRE)–Luc construct and pRL-TK
(where TK is thymidine kinase) were purchased from Clontech and Promega,
respectively. IRF7 and RIP antibodies were purchased from Santa Cruz; LMP1
antibody (cs 1-4) was purchased from DAKO; and the Flag-M2, Ub, and HA
antibodies were purchased from Sigma.
Transfections and luciferase assays. HEK293 cells in 12-well plates were
transfected with 0.1 g of IFN- promoter reporter plasmid or ISRE-Luc con-
struct, 0.1 g of pcIRF7, and 0.1 g of LMP1 or RIP unless otherwise noted.
Empty vector was used to equalize the total amount of DNA in the transfections.
pRL-TK (0.025 g) served as an internal transfection control. SVT35 and RIP-
deficient Jurkat cells (8.5  105) were transfected with 1.5 g of IFN- promoter
reporter plasmid, 2 g pcIRF7, 2 g pcLMP1, and 1.5 g of pRL-TK. All
transfections were done with Fugene 6 transfection reagent (Roche). Luciferase
assays were performed 18 to 24 h posttransfection with a dual luciferase assay kit
(Promega).
Immunoprecipitations and immunoblot analysis. Raji, DG75-TA, and DG75-
LMP1 cells were lysed in immunoprecipitation (IP) lysis buffer (10 mM Tris, pH
7.5, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 5 mM dithiothreitol, 0.2 mM Na
orthovanadate, and Complete protease inhibitors). Cell extracts (1 mg) were
incubated with 2 g IRF7 or RIP antibodies overnight at 4°C. Protein A/G-
Sepharose beads (Santa Cruz) were added and samples incubated for 1 h at 4°C.
Precipitates were washed five times with 10 volumes of IP lysis buffer and eluted
by boiling the beads for 5 min in 2 sodium dodecyl sulfate (SDS) loading buffer.
The eluted proteins were separated by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to nitrocellulose membranes followed by immu-
noblotting with the indicated antibodies. HEK293 cells in 60-mm dishes and
RIP/ or RIP/ immortalized fibroblasts in 100-mm dishes were transfected
with combinations of Flag-IRF7, pcLMP1, and HA-Ub expression vectors with
the use of Lipofectamine 2000 (Invitrogen). Cells were harvested 24 to 48 h
posttransfection and lysed in IP lysis buffer. Cell extracts were incubated with 2
g Flag M2 antibody overnight at 4°C. Protein A/G-Sepharose beads were then
added, and samples were incubated for 1 h at 4°C and washed five times with 10
volumes IP lysis buffer. For sequential immunoprecipitations, the washed beads
were resuspended in 50 l 1% SDS and 1 mM dithiothreitol and heated to 95°C
for 5 min. After removal of the beads by centrifugation, the eluted proteins were
diluted 20-fold with IP lysis buffer and incubated with 2 g IRF7 antibody
overnight at 4°C. Protein A/G-Sepharose beads were added for 1 h at 4°C,
followed by five washes with 10 volumes of IP lysis buffer. The immunoprecipi-
tated proteins were eluted by boiling for 5 min in 2 SDS loading buffer and
separated by SDS-PAGE followed by immunoblotting with the indicated anti-
bodies.
RNA interference. HEK293 cells were transfected with RIP small interfering
RNA (siRNA) oligomer, purchased from Santa Cruz, with the use of Lipo-
fectamine 2000 according to the manufacturer’s instructions. The specific se-
quence is not supplied by the manufacturer. The control siRNA, which is a
scrambled sequence that does not lead to the specific degradation of any known
cellular mRNA, was also purchased from Santa Cruz. After 48 h, siRNA-treated
cells were transfected again with 0.1 g reporter plasmid, 0.1 g pcIRF7, and 0.1
g pcLMP1 with Lipofectamine 2000. Cells were harvested 24 h later. Luciferase
assays were performed as described above.
Retroviral production and infection. pBabe/RIP1 was made by PCR, subclon-
ing RIP1 into the pBabe/Hygro vector at the EcoRI/SalI site. 293T cells in
100-mm dishes were cotransfected with 7 g pVSV-G and pGAG-pol and either
7 g pBabe/GFP (where GFP is green fluorescent protein) or pBabe/RIP1 with
the use of a CalPhos mammalian transfection kit (BD Biosciences, Bedford,
MA). Supernatant fluids containing GFP or RIP1 retroviruses were collected
48 h later. For retroviral infections, RIP/ cells were plated in 100-mm dishes
and infected with GFP or RIP1 retroviruses in the presence of Polybrene (8
g/ml). The cells were selected in hygromycin (Invitrogen) for 2 weeks (40).
RESULTS
RIP1 activates IRF7. Although we have demonstrated pre-
viously that LMP1 activates IRF7 and enhances its transcrip-
tional activity (45), the mediators of this activation of IRF7
have not been identified. RIP interacts with LMP1 CTAR2
(14), but a specific role for RIP in LMP1 signaling has re-
mained unassigned. However, RIP mediates activation of
IRF3 in response to dsRNA (2), and thus we thought that RIP
may mediate activation of IRF7 by LMP1. To test this hypoth-
esis, we first examined whether expression of RIP enhances the
transcriptional activity of IRF7. HEK293 cells, which do not
express endogenous IRF7 under our culture conditions, were
transfected with IRF7, RIP, and an IFN- promoter reporter
plasmid, a target of IRF7 and commonly used index of IRF7
activity. Cotransfection of IRF7 and increasing concentrations
of RIP activated the IFN- promoter in a dose-dependent
manner. RIP’s effect on this promoter was dependent on IRF7;
very little if any activity was detected upon transfection of RIP
alone (Fig. 1A). The results suggest that RIP activates IRF7.
We next used a kd-RIP (K45A) mutant to examine whether
RIP’s enzymatic activity is required for activation of IRF7. The
combinations of IRF7 and wild-type RIP or kd-RIP both ac-
tivated the IFN- promoter (Fig. 1B). Thus, RIP’s kinase ac-
tivity is not required for the activation of IRF7.
RIP1 is involved in LMP1-mediated activation of IRF7. To
test further whether RIP is implicated in activation of IRF7 by
LMP1, we examined IRF7 transactivation of the IFN- pro-
moter reporter in response to LMP1 in RIP-deficient Jurkat
cells. Whereas very little activity was detected upon transfec-
tion of IRF7 or LMP1 alone into parental Jurkat cells, pro-
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moter activity was substantially increased upon cotransfection
of IRF7 and LMP1, indicating that LMP1 activates IRF7 in
these cells. However, the LMP1-plus-IRF7-dependent IFN-
promoter activity was reduced in RIP-deficient Jurkat cells
compared with that in parental Jurkat cells (Fig. 2A). In ad-
dition, we used siRNA targeting RIP to suppress its expression
in 293 cells (Fig. 2B) and then examined the ability of IRF7 to
transactivate an ISRE-luciferase reporter, another common
index of IRF7 activity, in response to LMP1. LMP1-plus-IRF7-
dependent ISRE activity was reduced significantly after treat-
ment with RIP siRNA oligomer compared with activity after
treatment with control siRNA (Fig. 2C). Together these data
demonstrate that RIP mediates activation of IRF7 by LMP1.
RIP1 and IRF7 interact. We next examined whether RIP
and IRF7 interact. Raji is a Burkitt’s lymphoma cell line that
expresses RIP and due to latent EBV infection also expresses
LMP1 and IRF7. Therefore, these cells are useful for examin-
ing the interaction of endogenously expressed RIP and IRF7.
RIP and IRF7 were immunoprecipitated from Raji cell lysates
with RIP and IRF7 antibodies, followed by immunoblotting for
RIP. Two bands, neither detected with the control antibody,
were observed upon immunoprecipitating RIP (Fig. 3A). The
74-kDa band corresponded to the expected size of RIP, while
the other was a more slowly migrating, most likely modified,
form of RIP. RIP is known to be ubiquitinated in response to
TNF- (6, 20, 49), and it is likely that RIP is ubiquitinated in
this system as well. Therefore, to determine if ubiquitinated
proteins immunoprecipitate with RIP, the samples were im-
munoblotted with an antibody to Ub, and bands, correspond-
ing to the size observed for the modified form of RIP, were
detected (Fig. 3B). These results indicate that RIP is ubiquiti-
nated in Raji cells. Interestingly, ubiquitinated RIP specifically
coimmunoprecipitated with IRF7 while very little if any un-
conjugated RIP was associated with IRF7 (Fig. 3A). Together,
these data suggest that IRF7 preferentially interacts with ubiq-
uitinated RIP in a physiological setting.
FIG. 1. RIP1 activates IRF7. (A) 293 cells were transfected with an IRF7 expression vector; 0, 10, 50, 100, 200, and 300 ng of RIP expression
vector; and an IFN- promoter luciferase construct. The 300 ng of RIP was used for the RIP-only sample. In all experiments, luciferase assays were
performed 24 h after transfection to measure promoter activity. Results are the averages  standard deviations of a representative experiment
performed in triplicate. Similar results were obtained in three independent experiments. (B) 293 cells were transfected with combinations of IRF7
and RIP or a kd-RIP (K45A) mutant, which were expressed at similar levels as determined by Western blotting. wt, wild type.
FIG. 2. RIP mediates LMP1-induced activation of IRF7. (A) Pa-
rental or RIP-deficient Jurkat cells were transfected with combinations of
IRF7 and LMP1 with the use of Fugene 6. Results are the averages 
standard errors of triplicate samples. (B) 293 cells were transfected
with control (Cont) or RIP siRNA (Santa Cruz) with the use of
Lipofectamine 2000. RIP expression was analyzed by Western blotting
72 h posttransfection. (C) 293 cells transfected with control (C) or RIP
(R) siRNA were incubated for 48 h before transfection with IRF7,
LMP1, and an ISRE-luciferase reporter. Luciferase assays were done
24 h after the second transfection. Results were similar in three inde-
pendent experiments. IB, immunoblotting.
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LMP1 stimulates ubiquitination of RIP. LMP1 signaling
is constitutively active. The detection of substantial amounts
of ubiquitinated RIP in Raji cells raises the question of
whether LMP1 signaling promotes the ubiquitination of
RIP. To examine the effect of LMP1 on RIP, we utilized
DG75 cells stably transfected with LMP1 or control vector.
DG75 is an EBV-negative Burkitt’s lymphoma cell line that
endogenously expresses IRF7 and RIP. RIP was immuno-
precipitated from DG75-LMP1 or DG75-TA control cell
lysates, and the amounts of unconjugated and ubiquitinated
RIP were compared by Western blotting. Although levels of
unconjugated RIP were similar in the immunoprecipitates
from both cell lines, more ubiquitinated RIP was consis-
tently detected in the LMP1-positive cells (Fig. 3C). These
data indicate that LMP1 promotes ubiquitination of RIP
and suggest that some signals transduced through RIP by
LMP1 may be Ub dependent.
LMP1 stimulates the interaction of RIP with IRF7. The
facts that RIP contributes to activation of IRF7 by LMP1
and that LMP1 promotes the ubiquitination of RIP and its
association with IRF7 in cells suggest that interaction of
RIP with IRF7 is part of the mechanism for activation of
IRF7. Therefore, we next used DG75 cells stably transfected
with LMP1 to ask specifically whether LMP1 promotes the
association between RIP and IRF7. Immunoprecipitation of
IRF7 from DG75-LMP1 or DG75-TA cell lysates followed
by immunoblotting for RIP revealed that ubiquitinated RIP
interacted with IRF7 in DG75-LMP1 cells (Fig. 3D, left),
similarly to what was observed in Raji cells (Fig. 3A). RIP
immunoprecipitated with RIP antibody from DG75-LMP1
cells was included to provide a size marker for unconjugated
and ubiquitinated RIP. However, we detected little if any
RIP coimmunoprecipitating with IRF7 from DG75-TA cells
(Fig. 3D, left), although similar amounts of IRF7 were im-
munoprecipitated from both the LMP1-positive and the
LMP1-negative cell lines (Fig. 3D, right). These data sug-
gest that LMP1 stimulates the interaction between endoge-
nous IRF7 and ubiquitinated RIP.
LMP1 stimulates ubiquitination of IRF7. The interaction
between endogenous RIP and IRF7 in Raji cells was detected
in both experimental sequences: immunoprecipitation of RIP
followed by immunoblotting for IRF7 revealed that a small
amount of IRF7 immunoprecipitated nonspecifically with the
control antibody. However, much more IRF7 coimmunopre-
FIG. 3. LMP1 promotes ubiquitination of RIP and its interaction with IRF7. IRF7 and RIP were immunoprecipitated from Raji cell lysates
with IRF7 and RIP antibodies, respectively. Normal rabbit immunoglobulin G (IgG) was used for control (cont) immunoprecipitations. Immu-
noprecipitated proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and then immunoblotted (IB) with (A) RIP or
(B) Ub antibodies. The arrow indicates RIP; modified forms of RIP are marked with braces. Molecular size markers (in kilodaltons) are noted
at the left of blots. (C) RIP was immunoprecipitated from DG75 cells stably transfected with control vector (DG75-TA) or LMP1 (DG75-LMP1).
Immunoprecipitated proteins were immunoblotted with RIP antibodies. (D) IRF7 was immunoprecipitated from DG75-TA and DG75-LMP1
cells. Immunoprecipitated proteins were immunoblotted with RIP antibody (left). RIP immunoprecipitated with RIP antibody is shown for
comparison. Similar amounts of IRF7 were immunoprecipitated from both cell lines (right).
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cipitated with RIP (Fig. 4A). Interestingly, high-molecular-
weight, most likely modified, forms of IRF7 were detected
upon immunoprecipitation of IRF7, and these modified forms
of IRF7 also interacted with RIP (Fig. 4A). IRF7 has recently
been shown to be activated in a Ub-dependent manner (16),
and the diffuse nature of the band is consistent with ubiquiti-
nation. Moreover, ubiquitinated proteins were immunopre-
cipitated with IRF7 from Raji cell lysates (Fig. 3B).
That modified—probably ubiquitinated—IRF7 interacts
with RIP in Raji cells suggests that IRF7 may be ubiquitinated
in response to LMP1 signaling. Therefore, we determined
whether LMP1 promotes ubiquitination of IRF7. After trans-
fection of 293 cells with HA-Ub and Flag-tagged IRF7 expres-
sion vectors alone or together with an LMP1 expression vector,
cells were lysed and IRF7 was immunoprecipitated with Flag
antibody followed by immunoblotting for HA or Flag. Cotrans-
fection of LMP1 and IRF7 produced additional slowly migrat-
ing forms of IRF7 not readily detected in the absence of LMP1
(Fig. 4B, left). Furthermore, consistently more Ub was immu-
noprecipitated from lysates containing both IRF7 and LMP1
(Fig. 4B, right). Together these data suggest that LMP1 pro-
motes ubiquitination of IRF7.
Several types of polyubiquitin chains linked through distinct
lysines of Ub may have different functional outcomes. Poly-
ubiquitination linked through K48 targets proteins for protea-
somal-dependent degradation. However, polyubiquitination
linked through other Ub lysines, such as K63, can have pro-
teasome-independent functions, which include regulating pro-
tein-protein interactions and activation of signaling molecules,
such as IKK (35). Therefore, we next asked whether LMP1 can
promote K63-linked ubiquitination of IRF7. A Ub vector in
which all lysine residues except K63 are mutated to arginine
(HA-K63-only Ub) (4) along with Flag-IRF7 alone or in com-
bination with LMP1 was transfected into 293 cells. Sequential
immunoprecipitations were used to favor detection of ubiquiti-
nated IRF7 but not ubiquitination of factors associating with
IRF7. Proteins immunoprecipitated first with Flag antibody
were heated to 95°C for 5 min in 1% SDS, followed by a second
immunoprecipitation with IRF7 antibody. Interestingly, immu-
noblotting for HA revealed low levels of spontaneous ubiquiti-
nation of IRF7 upon cotransfection of K63-only Ub. However,
addition of LMP1 clearly increased the amount of ubiquiti-
nated IRF7 (Fig. 4C, right). Moreover, immunoblotting for
Flag revealed a high-molecular-weight smear, consistent with
an increase in ubiquitinated protein, in the LMP1-positive
sample that was barely detectable in the LMP1-negative sam-
ple (Fig. 4C, left). These results indicate that LMP1 promotes
K63-linked ubiquitination of IRF7.
Ub enhances IRF7 activity. That LMP1 promotes ubiquiti-
nation of IRF7 at least in part through K63-linked Ub suggests
that Ub may regulate the activity of IRF7. To test further
whether ubiquitination affects IRF7 transcriptional activity,
293 cells were transiently transfected with expression vectors
for IRF7 and HA-tagged Ub together with an ISRE-luciferase
reporter construct. The coexpression of IRF7 and Ub resulted
in a dose-dependent increase in ISRE activity (Fig. 5A). More-
over, coexpression of IRF7 and the K63-only Ub mutant also
increased ISRE activity (Fig. 5B). The results indicate that Ub
enhances the activation of IRF7.
FIG. 4. LMP1 promotes ubiquitination of IRF7. (A) IRF7 coimmunoprecipitates with RIP from Raji cell lysates. Proteins immunoprecipitated
with IRF7 or RIP antibodies were immunoblotted (IB) for IRF7. IRF7 is indicated by an arrow; high-molecular-weight, modified forms of IRF7
are indicated by brackets. IgG cont, immunoglobulin G control. (B) Combinations of Flag-IRF7, LMP1, and HA-Ub expression vectors were
transiently transfected into 293 cells. Proteins were immunoprecipitated with Flag antibody and immunoblotted with Flag or HA antibodies.
(C) Combinations of Flag-IRF7, LMP1, and HA-K63-only Ub vectors were transiently transfected into 293 cells. Proteins immunoprecipitated with
Flag antibody were boiled and reprecipitated with IRF7 antibody prior to immunoblotting with Flag or HA antibodies. The asterisk indicates a
nonspecific band. Molecular size markers (in kilodaltons) are noted next to blots.
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RIP contributes to LMP1-promoted ubiquitination of IRF7.
Because RIP interacts with unconjugated and ubiquitinated
IRF7 and contributes to activation of IRF7 by LMP1, we next
asked whether RIP contributes to the ubiquitination of IRF7
promoted by LMP1. RIP/ and RIP/ immortalized fibro-
blasts were transfected with HA-Ub and Flag-IRF7 with or
without LMP1. Flag-IRF7 was immunoprecipitated with Flag
antibody. The samples were boiled and reprecipitated with
IRF7 antibody before detection of ubiquitination by immuno-
blotting for HA. Ubiquitinated IRF7 detected in small
amounts in RIP/ cells in the absence of LMP1 was greatly
increased by LMP1 (Fig. 6A, top). In striking contrast, ubiq-
uitination of IRF7 was not detected in RIP/ cells even in the
presence of LMP1, although similar amounts of IRF7 were
present in each sample (Fig. 6A, bottom). Finally, reconstitu-
tion of RIP/ cells with RIP restored ubiquitination of IRF7
(Fig. 6B). The results indicate that RIP mediates LMP1-pro-
moted ubiquitination of IRF7.
TRAF6 may be involved in LMP1-mediated activation of
IRF7. TRAF6, a Ub ligase that catalyzes K63-linked Ub
chains, interacts with and activates IRF7 in a Ub-dependent
manner in response to TLR9 signaling (16). Therefore, we next
examined whether TRAF6 is involved in LMP1-mediated ac-
tivation of IRF7. After transfection of IRF7 and LMP1 or RIP
with and without TRAF6DN into 293 cells, we assessed acti-
vation of an ISRE-luciferase reporter by IRF7. TRAF6DN
blocked IRF7 activation by both LMP1 and RIP (Fig. 7), a
result consistent with the idea that TRAF6 is involved in
LMP1/RIP-mediated IRF7 activation.
DISCUSSION
IRF7 is the master regulator of IFN-/ responses (11), and
it also affects other target genes (28, 45). Since the stimuli are
diverse, the mechanisms that govern the activity of IRF7 are
likely to be complex and are important to understand. We have
FIG. 5. Ub enhances IRF7 activity. 293 cells were transiently transfected with an ISRE-luciferase reporter and combinations of IRF7 and the
indicated amounts of (A) HA-Ub vector or (B) HA-K63-only Ub vector. Results shown are averages  standard deviations.
FIG. 6. RIP mediates LMP1-promoted ubiquitination of IRF7. Combinations of Flag-IRF7, LMP1, and HA-Ub vectors were transiently
transfected into (A) RIP/ or wild-type-RIP fibroblast cells or (B) RIP/ fibroblasts reconstituted with RIP. Proteins immunoprecipitated with
Flag antibody were boiled and reprecipitated with IRF7 antibody and immunoblotted (IB) with HA or Flag antibodies. RIP expression in
reconstituted RIP/ cells is shown on the right.
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shown previously that LMP1 activates IRF7, promoting its
phosphorylation and nuclear accumulation (45). Here we show
that LMP1 promotes the ubiquitination of IRF7, which en-
hances its activity. RIP is a crucial element in mediating this
ubiquitination, but activation of IRF7 does not require RIP’s
enzymatic activity. RIP has long been suspected to participate
in LMP1 signaling, and we define here for the first time its
important role. Finally, we show evidence that suggests that the
regulatory ubiquitination of IRF7 brought about by LMP1 may
use TRAF6 as an E3 ligase.
It may seem paradoxical that LMP1 upregulates (44) and
activates IRF7, in light of its central role in the IFN response.
However, IRF7’s role may be in priming of latently EBV-
infected cells by LMP1 for IFN production, the effect of which
is to inhibit lytic EBV replication and superinfection by other
viruses and thus to avert disruption of latency (42). Mainte-
nance of latency is important for viral persistence because
EBV, particularly the lytic antigens, generates robust cytotoxic-
T-cell responses (30). In addition, LMP1 may utilize IRF7 for
functions other than IFN responses. Indeed, LMP1 and IRF7
participate in a regulatory circuit that potentiates the expres-
sion of both factors (28). By increasing LMP1 expression, IRF7
may have an impact on LMP1’s oncogenic potential (48).
The findings that IRF7 is modified by K63-linked Ub and the
results of assays indicating that expression of Ub increases
IRF7 activity are consistent with the idea that the activity of
IRF7 in the LMP1 pathway is regulated in part by its ubiquiti-
nation. These findings certainly do not exclude the ubiquitina-
tion of IRF7 through other lysine linkages; in fact, IRF7 is
known to undergo Ub-dependent degradation by the protea-
some (43). In addition, Ub likely enhances IRF7 activity by
promoting the activation of upstream kinases and signaling
intermediates as well.
IRF7 is regulated in response to varied stimuli, and ubiq-
uitination coupled in an undetermined sequence with phos-
phorylation may be a general mechanism for its activation.
Both LMP1- and TLR9-induced activation of IRF7 invoke
both phosphorylation and ubiquitination. Whether the two
modifications are linked or can function independently is un-
der study. The different degrees of IRF7 phosphorylation that
follow viral infection may affect the magnitude of responses
mediated by IRF7 (5). Ubiquitination of IRF7 would then
provide an additional level of control that modulates these
responses. Further, because polyubiquitin chains can facilitate
the assembly of protein complexes (15), ubiquitination of IRF7
may modify its ability to interact with various transcriptional
coregulators, thus influencing the selection of target genes.
LMP1 also promotes the ubiquitination of RIP and the
interaction of ubiquitinated RIP with IRF7. Importantly in our
study, preferential interaction of endogenous IRF7 with ubiq-
uitinated RIP was detected under physiological conditions in
EBV latently infected Raji cells. These findings probably have
broader importance, as a complex containing RIP and IRF7
forms upon stimulation with poly(IC) as well (M. Kelliher,
unpublished observations). Upon TNF stimulation, RIP is
ubiquitinated (6, 20, 49), which is speculated to allow the
recruitment of the TAK1/TAB2 complex (15) and is required
for TNF signaling (19). Thus, our observations of ubiquitinated
RIP specifically interacting with IRF7 may provide some in-
sight into how LMP1 stimulates RIP to transduce signals.
Polyubiquitin chains are envisioned as functioning as scaf-
folds for the assembly of signaling complexes that bring kinases
and substrates into close proximity (15). In the case of ubiq-
uitinated RIP, in complex with IRF7, the signaling components
might include a Ub ligase for IRF7, possibly TRAF6. TRAF6
is a likely candidate as an E3 ligase for IRF7 in LMP1/RIP
signaling since it along with Ubc13 and Uev1A/Mms2 catalyzes
K63-linked ubiquitination (7). Moreover, TRAF6 interacts
with RIP through the adaptor protein p62 in IKK activation
(31). TRAF6 also interacts with IRF7 (10, 16) and functions in
the Ub-dependent activation of IRF7 in the TLR9/MyD88/
TRAF6 pathway (16). Our data demonstrating that
TRAF6DN blocks activation of IRF7 by both LMP1 and RIP
are consistent with the idea that TRAF6 functions in the
LMP1/RIP pathway as well. However, further studies with
FIG. 8. Model for LMP1 activation of IRF7. LMP1 stimulates the
ubiquitination of RIP associated with CTAR2. Ubiquitinated RIP
functions as a scaffold where it interacts with IRF7 and possibly
TRAF6 through p62. TRAF6 catalyzes K63-linked ubiquitination of
IRF7 (indicated by a dotted arrow and a question mark), leading to
enhanced IRF7 transcriptional activity. CTAR1-dependent activation
of IRF7 may also involve TRAF6 (indicated by a dotted arrow and a
question mark).
FIG. 7. TRAF6DN blocks IRF7 activation by LMP1 and RIP.
Combinations of IRF7 and LMP1 or RIP with and without TRAF6DN
were transfected into 293 cells. Activity of IRF7 was assessed with an
ISRE-luciferase reporter. Results shown are averages  standard de-
viations.
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several systems are needed to demonstrate whether TRAF6 is
in fact responsible for the ubiquitination of IRF7 induced by
LMP1. The RIP/IRF7 complex likely also contains an IRF7
kinase, such as TBK1 or IKKε. In fact, RIP, in conjunction with
FADD and TBK1, is required for dsRNA-dependent activa-
tion of IRF3 (2). That RIP interacts with and promotes the
ubiquitination and activation of IRF7 and that it is required for
activation of IRF3 by dsRNA (2) suggest that RIP, in addition
to its role in NF-B activation, may be a general activator of
these IRFs, facilitating the assembly of several potentially dis-
tinct signaling complexes.
IRF7 activity is reduced but not absent in RIP-deficient
cells, and our data are compatible with additional mechanisms
that are independent of RIP. RIP interacts with LMP1
CTAR2, and it is likely that RIP facilitates CTAR2-dependent
activation of IRF7 (Fig. 8). LMP1 can also activate IRF7 via
CTAR1 (45; data not shown). The signaling cascade down-
stream of CTAR1 for the activation of IRF7 is unknown and is
likely independent of RIP but may involve TRAF6. TRAF6
colocalizes with LMP1 (33) and participates in signaling events
downstream of both CTAR1 and CTAR2 (25, 33, 39). The role
of TRAF6 in LMP1 signaling through CTAR2 and RIP but
also independently through CTAR1 is likely to be defined as
interrelated aspects of a complex mechanism and is under
study.
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